FDA Grants Orphan Drug Designation to Dewpoint Therapeutics’ DPTX3186 for the Treatment of Gastric Cancer
First orphan designation ever granted to a condensate-modulating therapeutic Builds on recent IND opening for DPTX3186, a first-in-class oral condensate modulator targeting the Wnt/B-catenin pathway Provides key regulatory and commercial advantages, including seven years of U.S. market exclusivity upon approval and eligibility for expedited FDA review BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) — Dewpoint Therapeutics, […]